Top-Rated Stocks NASDAQ:ITCI Intra-Cellular Therapies - ITCI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $54.15 -1.90 (-3.39%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$53.26▼$56.2050-Day Range$43.80▼$56.9952-Week Range$42.01▼$66.00Volume1.56 million shsAverage Volume775,560 shsMarket Capitalization$5.16 billionP/E RatioN/ADividend YieldN/APrice Target$71.92 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies MarketRank™ ForecastAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside32.8% Upside$71.92 Price TargetShort InterestHealthy2.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.07Based on 25 Articles This WeekInsider TradingSelling Shares$12.60 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.82 out of 5 starsMedical Sector42nd out of 1,004 stocksPharmaceutical Preparations Industry10th out of 489 stocks 4.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.92, Intra-Cellular Therapies has a forecasted upside of 32.8% from its current price of $54.15.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.74% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently decreased by 21.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 1.7 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Intra-Cellular Therapies this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,596,937.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions86.95% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.43) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -19.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -19.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 7.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intra-Cellular Therapies (NASDAQ:ITCI) StockIntra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.Read More Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Stock News HeadlinesMarch 31, 2023 | finance.yahoo.comIntra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?March 31, 2023 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $87.00 at Cantor FitzgeraldApril 1, 2023 | Vantage Point (Ad)The Market Crash Shield is A.I.Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. March 30, 2023 | benzinga.comIntra-Cellular Therapies Stock (NASDAQ:ITCI), Guidance and ForecastMarch 30, 2023 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $63.00March 30, 2023 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Given New $74.00 Price Target at MizuhoMarch 29, 2023 | msn.comIntra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock UpMarch 29, 2023 | seekingalpha.comIntra-Cellular Therapies: Increased Confidence In MDD After Study 403 SuccessApril 1, 2023 | Vantage Point (Ad)The Market Crash Shield is A.I.Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. March 29, 2023 | finance.yahoo.comIntra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?March 29, 2023 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI): When Will It Breakeven?March 28, 2023 | msn.comIntra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed FeaturesMarch 28, 2023 | finance.yahoo.comThe 21-Million-Person Market That Just Drove Intra-Cellular To A 7-Month HighMarch 28, 2023 | finance.yahoo.comWhy Intra-Cellular Therapies Climbed TuesdayMarch 28, 2023 | seekingalpha.comIntra-Cellular jumps 14% after early data for depression candidateMarch 28, 2023 | msn.comIntra-Cellular’s stock jumps on new data for depression drugMarch 28, 2023 | msn.comITCI Gains on Promising Results in Depression TreatmentMarch 28, 2023 | finance.yahoo.comIntra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed FeaturesMarch 7, 2023 | msn.comIntra-Cellular Therapies's Return On Capital Employed OverviewMarch 3, 2023 | benzinga.comIntra-Cellular Therapies Stock (NASDAQ:ITCI), Analyst Ratings, Price Targets, PredictionsMarch 3, 2023 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finance.yahoo.comIntra-Cellular Therapies Full Year 2022 Earnings: EPS Beats ExpectationsMarch 1, 2023 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateFebruary 28, 2023 | msn.comEarnings Outlook For Intra-Cellular TherapiesFebruary 24, 2023 | benzinga.comIntra-Cellular Therapies Stock (NASDAQ:ITCI), Quotes and News SummaryFebruary 14, 2023 | finance.yahoo.comIntra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and WebcastFebruary 8, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the SVB Securities Global Biopharma ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Company Calendar Last Earnings3/01/2023Today3/31/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees512Year FoundedN/APrice Target and Rating Average Stock Price Forecast$71.92 High Stock Price Forecast$98.00 Low Stock Price Forecast$49.00 Forecasted Upside/Downside+32.8%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-256,260,000.00 Net Margins-102.37% Pretax Margin-102.37% Return on Equity-35.88% Return on Assets-31.86% Debt Debt-to-Equity RatioN/A Current Ratio8.87 Quick Ratio8.58 Sales & Book Value Annual Sales$250.31 million Price / Sales20.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book7.81Miscellaneous Outstanding Shares95,280,000Free Float91,755,000Market Cap$5.16 billion OptionableOptionable Beta1.13 Key ExecutivesSharon MatesChairman, President & Chief Executive OfficerLawrence J. HinelineChief Financial Officer, Treasurer & SVP-FinanceRobert E. DavisChief Scientific Officer & Senior Vice PresidentSuresh DurgamChief Medical Officer & Senior Vice PresidentKaren Patruno SheehyChief Compliance Officer & Senior Vice PresidentKey CompetitorsPrometheus BiosciencesNASDAQ:RXDXOrganon & Co.NYSE:OGNIonis PharmaceuticalsNASDAQ:IONSRoivant SciencesNASDAQ:ROIVGrifolsNASDAQ:GRFSView All CompetitorsInsiders & InstitutionsMetropolitan Life Insurance Co. NYBought 223 shares on 3/31/2023Ownership: 0.006%Mark NeumannSold 15,604 sharesTotal: $847,453.24 ($54.31/share)Sharon MatesSold 20,565 sharesTotal: $925,219.35 ($44.99/share)Suresh K DurgamSold 7,344 sharesTotal: $330,773.76 ($45.04/share)Lawrence J. HinelineSold 5,582 sharesTotal: $250,799.26 ($44.93/share)View All Insider TransactionsView All Institutional Transactions ITCI Stock - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price forecast for 2023? 11 brokerages have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they predict the company's stock price to reach $71.92 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2023? Intra-Cellular Therapies' stock was trading at $52.92 on January 1st, 2023. Since then, ITCI shares have increased by 2.3% and is now trading at $54.15. View the best growth stocks for 2023 here. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 2,610,000 shares, a decrease of 21.1% from the February 28th total of 3,310,000 shares. Based on an average trading volume of 672,700 shares, the days-to-cover ratio is presently 3.9 days. View Intra-Cellular Therapies' Short Interest. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company had revenue of $87.87 million for the quarter, compared to the consensus estimate of $86.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 35.88% and a negative net margin of 102.37%. Intra-Cellular Therapies's revenue for the quarter was up 242.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) EPS. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include Psyk Etf (PSYK), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (2.13%), Franklin Resources Inc. (1.89%), Geode Capital Management LLC (1.76%), JPMorgan Chase & Co. (1.58%), GW&K Investment Management LLC (1.53%) and Millennium Management LLC (1.47%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $54.15. How much money does Intra-Cellular Therapies make? Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. How many employees does Intra-Cellular Therapies have? The company employs 512 workers across the globe. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334. This page (NASDAQ:ITCI) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.